Anifrolumab met primary and secondary endpoints in Phase 2 significantly reducing lupus disease activity compared with placebo across multiple endpoints

Under the initial collaboration, partners launch the seventh company, Iron Horse Therapeutics, developing novel treatments for ALS (amyotrophic lateral sclerosis)

Pancreatic, breast, mesothelioma and and glioblastoma multiforme cancers are highlighted

Heat Biologics reports HS-410 Phase 1 bladder cancer trial results at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Company presents preclinical data on G100 and ZVex in combination with check point inhibitors at the 2015 Society for Immunotherapy of Cancer Annual Meeting

Affinivax announces collaboration with ClearPath and Astellas to develop vaccines to prevent nosocomial infections

The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Janssen has optioned 11 programs out of a total of 20 programs under the bispecific DuoBody platform collaboration with Genmab.

Researchers have demonstrated a new, highly precise way to switch the control sequences of the human genome on or off without changing the underlying DNA sequence.

In a pair of developments, Emulate, Inc. has advanced its organs-on-chips program development.

Clinical response and mucosal healing significantly improved with Ozanimod 1 mg compared to placebo at week 32

Third Rock Ventures launches Decibel Therapeutics with $52 million series A financing to discover new medicines to protect, repair and restore hearing

Oncology Research Information Exchange Network could make huge steps to bring together oncology research, oncology patients and drug developers